Aggregative α-synuclein and incurring oxidative stress are pivotal cascading events, leading
to dopaminergic (DAergic) neuronal loss and contributing to clinical manifestations of …

Therapeutic options for Parkinson's disease (PD) are limited to a symptomatic approach,
making it a global threat. Targeting aggregated alpha-synuclein (α-syn) clearance is a gold …

Background Aggregation and neurotoxicity of the presynaptic protein α-synuclein and the
progressive loss of nigral dopaminergic neurons are believed to be the key hallmarks of …

The α-synucleinopathies constitute a subset of neurodegenerative disorders, of which
Parkinson's disease (PD) is the most common worldwide, characterized by the accumulation …

Parkinson's disease (PD) is the most frequent neurodegenerative movement disorder.
Presently, there is no causal therapy available to slow down or halt disease progression …

α-Synuclein accumulation is implicated in the pathogenesis of neurodegenerative diseases,
including Parkinson's disease (PD). Previously, we reported that Fas-associated factor 1 …

Background Overexpression and abnormal accumulation of aggregated α-synuclein (αS)
have been linked to Parkinson's disease (PD) and other synucleinopathies. αS can misfold …

Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are neurodegenerative
disorders characterized by the misfolding and aggregation of alpha-synuclein (aSyn) …

Cannabidivarin (CBDV), a structural analog of cannabidiol (CBD), has received attention in
recent years owing to its anticonvulsant property and potential for treating autism spectrum …

Parkinson's disease (PD) is the most common motor-associated neurodegenerative
disease. Although the pathogenesis of PD is still wrapped in the mist, accumulating …